Results from the NRG Oncology GOG-0263 phase III clinical trial testing the addition of cisplatin-based chemotherapy to adjuvant radiotherapy following radical hysterectomy and lymphadenectomy for patients with early-stage, intermediate-risk cervical carcinoma indicated that the addition of chemotherapy did not improve outcomes for patients and led to increased toxicity for patients.
Protesters slam health insurance lobby for Medicare Advantage coverage restrictions
WASHINGTON — Hundreds of activists rallied today outside of the headquarters of the country’s largest health insurance lobbying group to protest against restrictions to coverage
June 27, 2023